Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P19438
UPID:
TNR1A_HUMAN
Alternative names:
Tumor necrosis factor receptor 1; Tumor necrosis factor receptor type I; p55; p60
Alternative UPACC:
P19438; A8K4X3; B2RDE4; B3KPQ1; B4DQB7; B4E309; B5M0B5; D3DUR1; Q9UCA4
Background:
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), also known as p55 or p60, plays a pivotal role in immune and inflammatory responses. It acts as a receptor for TNF-alpha, initiating apoptosis and contributing to anti-viral states through the activation of caspase-8 and acid sphingomyelinase.
Therapeutic significance:
TNFRSF1A's involvement in Periodic fever, familial, autosomal dominant, and its association with Multiple sclerosis 5, highlights its potential as a therapeutic target. Understanding its role could lead to novel treatments for these inflammatory and autoimmune conditions.